RATsIONAL'NYY VYBOR FARMAKOTERAPII POSTMENOPAUZAL'NOGO OSTEOPOROZA.EFFEKTIVNOST' I BEZOPASNOST' BONVIVY: OBZOR ZA VOSEM' LET PRIMENENIYa
Abstract
In this critical review, we have summarized the specific evidence on ibandronic acid (Bonviva) efficacy, tolerability, feasibility and safety acquired from randomized controlled clinical trials, meta-analyses, bridging trials, long-term extension studies, observational studies and clinical experience. We have paid special attention to reviewing the surrogate endpoints, which are routinely used in clinical practice to estimate the treatment efficacy as well as those high technology methods that are currently used in research centers to predict anti-fracture efficacy. Although the only registered indication for Bonviva in Russia is for postmenopausal osteoporosis, we have reviewed the available clinical trials on the efficacy of ibandronic acid to prevent postmenopausal osteoporosis, to treat low bone mass in males, to treat and prevent glucocorticoid induced osteoporosis and other types of secondary osteoporosis and, in particular, in patients after organ transplantation. In addition to this, we have extensively discussed the currently available data on the safety of pharmacologic treatment for osteoporosis.
References
1. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я.: «Остеопороз — от редкого симптома эндокринных болезней до безмолвной эпидемии 20—21 века»// Ж. Проблемы Эндокринологии, 2011, том 57, стр.35—45.
2. Cummings SR, Melton LJ 3rd. Epidemiology and outcomes of osteoporosis fractures. Lancet. 2002, Vol. 359, pp. 1761—1767.
3. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med., 1997, Vol. 103, pp. 12S—17S.
4. Kanis J.A, McCloskey EV, Johansson H, Cooper C, Rizolli R, Reginster R, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF).: European guidance for the diagnosis and management of osteoporosis in postmenopausal women.// Osteoporosis International, 2013, Vol. 24, pp. 23—57.
5. Fleisch H, Neuman WF.: Mechanisms of calcification: role of collagen, polyphosphates and phosphatase. Amer J. Physiol, 1961, Vol. 200: 1296; Fleish H, Bisaz S.: Isolation from urine of pyrophosphate, a calcification inhibitor. Amer J. Physiol., 1962, Vol. 203: 671.
6. Fleisch H, Russell RGG, Straumann F.: Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature (London), 1966, Vol. 212: 901.
7. Russel RGG, Bisaz S, Fleisch H.: Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure. Arch. Intern. Med., 1969, Vol. 124: 571.
8. Russell RGG, Bisaz S, Donath A, Morgan DB, Fleisch H.: Inorganic Pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. The J. Clinical Investigation, 1971, Vol. 50, pp. 961—969.
9. Black DM, Cummings SR, Karpf DB, et.al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 1996; 348: 1535—41.
10. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.// J. Bone Miner Res, 2004, Vol. 19, pp. 1241—1249.
11. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, et.al: Once-Yearly Zoledronic acid for treatment of postmenopausal osteoporosis.// New England J. Medicine, 2007, Vol. 356, pp. 1809—1822.
12. Sambrook P, Cooper C.: Osteoporosis. Lancet, 2006, Vol. 367, pp. 2010—2018.
13. Скрипникова ИА, Рожинская ЛЯ.: Применение дженериков — способ повышения приверженности лечению остеопороза.// Ж. Остеопороз и остеопатии, 2010, № 3, стр. 36—40.
14. Дедов ИИ, Рожинская ЛЯ, Белая ЖЕ: «Роль и место бисфосфонатов в профилактике и лечении остеопороза: 10-летний опыт применения алендроната, Ж. Остеопороз и остеопатии, 2005, № 1, стр. 20—30.
15. Белая Ж.Е., Рожинская Л.Я.: «Бисфосфонаты: мифы и реальность».// Ж. Эффективная фармакотерапия в эндокринологии, 2010, сентябрь, стр. 52—58.
16. Белая Ж.Е., Рожинская Л.Я.: «Бисфосфонаты в терапии постменопаузального остеопороза» Ж. Доктор Ру, 2010, Т.58 (№7), стр. 29—38.
17. Белая Ж.Е., Рожинская Л.Я. Сосунова Н.В.: Роль факторов риска в диагностике остеопороза и принятии решения о назначениии терапии. Эффективность бисфосфонатов в лечении остеопороза.// Русский Медицинский Журнал, 2009, Том 17, стр. 706—711.
18. Рожинская Л.Я., Белая ЖЕ: Достижения и перспективы в лечении остеопороза.//Ж. Профилактическая медицина, 2009, том 12, стр. 21—-26.
19. Белая Ж.Е., Рожинская Л.Я.: «Дженерики в терапии постменопаузального остеопороза»// Русский медицинский журнал, 2010, Том 18, (21 октября), стр. 1419—1422.
20. Торопцова НВ, Беневоленская ЛИ.: Результаты применения зо-ледроновой кислоты в лечении остеопороза. // Ж. Остеопороз и остеопатии, 2008, № 2, стр. 25—28.
21. Белая ЖЕ, Рожинская ЛЯ.: «Возможности применения паратиреоидного гормона для лечения остеопороза» Ж. Остеопороз и остеопатии, 2004, №3 стр 26—33.
22. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза — применение моноклональных человеческих антител к RANKL (Деносумаб) // Ж. Остеопороз и Остеопатии, 2011, № 2, стр. 19—22.
23. Brody BA, Dickey N, Ellenberg SS, et.al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J. Bone Miner Res, 2003, Vol. 18, pp. 1105—1109.
24. Temple RJ. Study designs in osteoporosis. J. Bone Miner Res, 2003, Vol. 18, pp. 1129—1132.
25. Felsenberg D, Miller P, Armbrecht G, et.al: Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone, 2005, Vol. 37, pp. 651—654.
26. Epstein S, Jeglitsch M, McCloskey E.: Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandro-nate 150 mg and risedronate 150 mg. Curr Med Res Opin, 2009, Vol. 25, pp. 2951—2960.
27. Cummings SR, Black DM, Thompson DE, et.al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial.// JAMA, 1998, Vol. 280, pp. 2077—2082.
28. Reginster J, Minne HW, Sorensen OH, et.al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. //Osteoporosis International, 2000, Vol. 11, pp. 83—91.
29. ReginsterJY, Seeman E, Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study.// J. Clinical Endocrinology and Metabolism, 2005, Vol. 90, pp. 2816—2822.
30. O’Donnel S, Cranney A, Wells GA, Adachi J, Reginster JY.: Strontium ranelate for preventing and treating osteoporosis// The Cochrane Library, 2008, Issue 4.
31. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, for the FREEDOM Trial: Deno-sumab for Prevention of Fractures in Postmenopausal Women with Osteopo-rosis.// New England J. Medicine, 2009, Vol.361, pp. 756—765.
32. Cranney A, Wells GA, Yetisir E, et.al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteo-poros. Int, 2009, Vol. 20, pp. 291—297.
33. Harris ST, Blumentals WA, Miller PD. : Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase 3 studies. Curr Ned Res Opin, 2005, Vol. 24, pp. 237—245.
34. Miller PD, McClung MR, Macovei L, et.al.: Monthly oral ibandro-nate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone and Miner Res, 2005, Vol. 20, pp. 1315—1322.
35. Reginster J-Y, Adami S, Lakatos S, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.// Ann Rheum Dis, 2006, Vol. 65, pp. 654—661.
36. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster J-Y, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.: Intravenous Ibandronate injections in postmenopausal women with osteoporosis.// Arthritis and Rheumatism, 2006, Vol. 54, pp. 1838—1846.
37. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.: Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: a 2-year results from the DIVA study. J. Rheumatol, 2008, Vol. 35, pp. 488—497.
38. Recker R, Stakkestad JA, Chesnut CH, et.al.: Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. //Bone 2004, Vol. 34, pp. 890—899.
39. Barret J, Worth E, Baus F.: Ibandronate: a clinical pharmacological and pharmacokinetic update.// J. Clin Pharmacol, 2004, Vol. 44, pp. 951—965.
40. Hochberg MC, Greenspan S, Wasnich RD, et.al.: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.// J. Clin Endocrinol. Metab, 2002, Vol. 87, pp. 1586—1592.
41. Hochberg MC, Ross PD, Black D, et.al.: Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arth Rheum, 1999, Vol. 42, pp. 1246—1254.
42. European Medicines Agency. Guideline on the Evaluation of New Medicinal Products in the Treatment of Osteoporosis. 2005. Available from: http://www.emea.eu.int/pdfs/human/ewp/055295en.pdf.
43. Rizzoli R, Greenspan SL, Bone G, et.al.: Two-year results of onceweekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J. Bone Miner Res, 2002, Vol. 17, pp. 1988—1996.
44. Brown JP, Kendler DL, McClung MR, et.al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int, 2002, Vol. 71, pp. 103—111.
45. Miller PD, Recker RR, Reginster J-Y, Riis BJ, Czerwinski E, Ma-sanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P.: Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.// Osteoporosis Int, 2012, Vol. 23, pp. 1747—1756.
46. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D.: Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis Int, 2012, Vol. 23, pp. 1769-— 1778.
47. Rossini M, Idolazzi L. Adami S.: Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review. Ther Adv Musskuloskel Dis, 2011, Vol. 3, pp. 67—79.
48. Engelke K, Fuerst T, Dasic G, et.al.: Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. // Bone, 2010, Vol. 46, pp. 1626—1632.
49. Lewiecki EM, Keaveny TM, Kopperdahl DL, et.al.: Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J. Clin Endocrinol Metab, 2009, Vol. 94, pp. 171—180.
50. Genant HK, Lewiecki EM, Fuerst T, et.al.: Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporosis Int., 2012, Vol. 23, pp. 257—265.
51. Chapurlat RD, Laroche M, Thomas T, et.al.: Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia - a randomized placebo-controlled trial. // Osteoporosis International, 2013, Vol. 24, pp. 311—320.
52. Recker RR, Ste-Marie LG, Langdahl B, et.al.: Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study. J.Clin Densitom, 2009, Vol. 12, pp. 71—76.
53. Bock O, Borst H, Beller G, et.al. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo muCT.// Bone, 2012, Vol. 50, pp. 317—324.
54. Recker RR, Ste-Marie LG, Langdahl B, et.al.: Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. // Bone, 2010, Vol. 46, pp. 660—665.
55. Bala Y, Kohles J, Recker RR, et.al.: Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. Calcified Tissue Int, 2013, Vol. 92, pp. 6—14.
56. Miller PD, Epstein S, Sedarati F, Reginster J.: Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.// Current Medical Research and Opinion, 2008, Vol. 24, pp. 207—213.
57. Siris ES, Harris ST, Rosen CJ, et.al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc, 2006, Vol. 81, pp. 1013—1022.
58. Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА.: Ибандронат (Бонвива) — новое направление в лечении бисфосфонатами. Лучшая приверженность к лечению — лучший результат. Ж. Остеопороз и остеопатии, 2006 N 3, стр. 23—29.
59. Cotte FE, Fardellone P, Mercier F, et.al.: Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. //Osteoporosis Int, 2010, Vol. 21, pp. 145-155.
60. Gatti D, Rossini M, Viapiana O, et.al.: Adherence to oral osteoporosis treatment in the Italian clinical practice.// Reumatismo, 2010, Vol. 62, (suppl), pp. 1—8.
61. Rossini M, Di Munno O, Gatti D, et.al.: Optimizing bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience. // Clin Exp Rheumatol, 2011, Vol. 29, pp. 728—735.
62. Belaya ZE.: Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG.// J. Rheumatology International 2011 Dec;31(12) pp.1669—1671.
63. Campbel MJ, Machin D.: Medical Statistis a commonsense approach, 2003, pp.62—63.
64. Silverman SL.: Osteoporosis therapies: evidence from health-care databases and observational population studies. Calcif. Tissue Int., 2010, Vol. 87, pp. 375—384.
65. Harris ST, Reginster JY, Harley C, et.al.: Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.// Bone, 2009, Vol. 44, pp. 758 —765.
66. Ringe JD, Dorst A, Faber H, et.al.: Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.// Osteoporosis Int, 2003, Vol. 14, pp. 801—807.
67. Li EK, Zhu TY, Hung VY, et.al.: Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther, 2010, Vol. 12, R 198.
68. Hakala M, Kroger H, Vallela H, Hienonen-Kempas T, Lentonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L, for the ONCE trial group.: Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12 month, randomized, double-blind, placebo-controlled trial. Scand. J. Rheumatol, 2012, Vol. 41, pp. 260—266.
69. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.: Efficacy and safety of monthly ibandronate in men with low bone density. Bone, 2010, Vol. 46, pp. 970—976.
70. Pasalic KS and ESTHER study group.: Efficacy and safety of once-monthly ibandronate treatment in patients with low bone mineral density — ETHER study: 24 months of follow-up.// Srp Arh Celok Lek, 2012, Vol. 140, pp. 722—727.
71. Pana Z, Hatzipantelis E, Douma S, Kateridou C.: Once monthly oral ibandronate treatment in an adolescent with recurrent fractures and inadequately low bone mass.// J. Paediatrics and Child Health, 2012, Vol. 48, pp. 619—623.
72. Fahrleinter-Pammer A, Piswanger-Soelkner JC, Pieber TR, Ober-mayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H.: Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.: J. Bone Miner Res, 2009, Vol. 24, pp. 1335—1344.
73. Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Hommann M, Sett-macher U.: Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.: Transplantation Proceedings, 2012, Vol. 44, pp. 1362—1367.
74. Smerud KT, Dolgos S, Olsen IC, Asberg A, Sagedal S, Reisater AV, Midtvedt K, Pfeffer P, Ueland T, Godang K, Bollerslev J, HartmannA.: A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.// American J. Transplantation, 2012, Vol. 12, pp. 3316—3325.
75. Jonville-Bera AP, Autrer-Leca E.: Adverse drug reactions of strontium ranelate (Protelos in France).: Presse Med., 2011, Vol. 40, pp. E 453—462.
76. European Medicines Agency: Questions and answers on the review of Protelos and Osseor (strontium ranelate) 15 March 2012 EMA/18304/2012.
77. European Medicines Agency.: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013.
78. Cacoub P, Descamps V, Meyer O, Speirs C, Belissa-Mathiot P, Musette P.: Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate.// Osteoporosis International, 2013, Vol. 24, pp. 1751—1757.
79. Rossini M, Bianchi G, Di Munno O, et.al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis International, 2006, Vol. 17, pp. 914—921.
80. Hamilton B, McCoy K, Taggart H.: Tolerability and compliance with risedronate in clinical practice.// Osteoporosis Int, 2003, Vol. 14, pp. 259—262.
81. Cryer B, Bauer DC.: Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc, 2002, Vol. 77, pp. 1031—1043.
82. Rossini M, Orsolini G, Adami S, Kunnathully V, Gatti D.: Osteoporosis treatment: why ibandronic acid?// Expert Opin Pharmacother. (early online) 2013.
83. Binkley N, Martens MG, Silverman SL, et.al. Improved GI toler-ability with monthly ibandronate in women previously using weekly bisphos-phonates.// South Med. J., 2009, Vol. 102, pp. 486—492.
84. Lewiecki EM, Babbitt AM, Piziak VL, et.al.: Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandro-nate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. // Clin Ther, 2008, Vol. 30, pp. 605—621.
85. Rossini M, Adami S, Viapiana O, et.al.: Circulating γ, δ T cells and the risk of acute-phase response after zoledronic acid administration. J. Bone Miner Res, 2012, Vol. 27, pp. 227—230.
86. Sieber P, Lardelli P, Kraenzlin A, Kranzilin ME, Meier C.: Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.// Clinical Drug Investigation, 2013, Vol. 33, pp. 117—122.
87. Miller PD, Ward P, Pfisret, et,all.,: Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: areview. Clin Exp Rheumatology, 2008, Vo. 26, pp. 1125—1133.
88. Miller PD. The kidney and bisphosphonates. Bone, 2011, Vol. 49, pp. 77—81.
89. Weide R, Koppler H, Antras L., et.al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vc. Ibandronate: a retrospective medical records review. J. Cancer Res Ther, 2010, Vol. 6, pp. 31—35.
90. Body JJ, Pfister T, Bauss F.: Preclinical perspectives on bisphosphonate renal safety. Oncologist, 2005, Vol. 19, suppl: 3—7.
91. Miller PD, Ragi-Eis S, Mautalen C, et.al.: Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease — the DIVINE study. Bone, 2011, Vol. 49, pp. 1317—1322.
92. Ettinger MP, Felsenberg D, Harris ST, Wasnich R, Skag A, Hiltbrun-ner V, Wilson K, Schimmer RC, Miller PD.: Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age// J. Rheumatology, 2005, Vol. 32, pp. 1968—1974.
93. Pazianas M.: Osteonecrosis of the jaw and the role of macrophages //JNCI, 2011, Vol. 103, pp. 232—240.
94. Editor’s note: Phosphorous necrosis under control. B. Dent., 1944, Vol. 76, p. 343; Pazianas M.: Osteonecrosis of the jaw and the role of macrophages //JNCI, 2011, Vol. 103, pp. 232—240.
95. Marx RE.: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.// J. Oral Maxillofac Surg, 2003, Vol. 61, pp. 1115—1117.
96. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL.: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac Surg. 2004, Vol. 62, pp. 527—534.
97. Filleul F, Crompot E, Saussez S.: Bisphosphonate-induced osteonecrosis of the jaw: a review of 2400 patient cases. J. Cancer Res Clin Oncol, 2010, Vol. 136, pp. 1117—1124.
98. Brown JE, Barrios CH, Diel IJ, et.al. Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. In: 10th International Conference on Cancer-Induced Bone Disease; September 22-25, 2010 Sheffield, UK. OC—15.
99. Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN.: Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. J. Oral Maxillofac Surg, 2012, Vol. 70, pp. 2768—2775.
100. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R.: Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.// Oral Surg Oral Med Oral Pathol Oral Radiol En-dod, 2008, Vol. 106, pp. 389—391.
101. Anastasilakis AD, Toulis KA, Goulis DG, et.al.: Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. // Horm. Metab Res, 2009, Vol. 41, pp. 721—729.
102. Howe TS, Erlich G, Koh JSB, Ng ACM, Costertom W.: A case of an atypical femoral fracture associated with bacterial biofilm — pathogen or bystander?” Osteoporosis Int, 2013, Vol. 24, pp. 1765—1766.
103. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H.: Managing the care of patients receiving antire-sorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs.// JADA, 2011, Vol. 142, pp. 1243—1251.
104. European Medicines Agency.: CHMP assessment report on bisphosphonates and osteonecrosis of the jaw. London 24 September 2009 EMEA/ CHMP/291125/2009.
105. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA.: Ten years’ experience with alendronate for osteoporosis in postmenopausal women.// NEJM, ]. 2004, Vol. 350, pp. 1189—1199.
106. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cos-man F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzy ME, Su G, Eastell R.: The Effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the Horizon-Pivotal fracture trial (PFT).// JBMR, 2012, Vol. 27, pp. 243—254.
107. Mozzati M, Arata V, Gallesio G.: Tooth extraction in osteoporotic patients taking oral bisphosphonates.// Osteoporosis Int, 2013, Vol. 24, pp. 1707—1712.
108. Khan AA, Sandor GK, Dore E, et.al.: Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol, 2009, Vol. 36, pp. 478—490.
109. Hoff AO, Toth BB, Altundag K, et.al.: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.// JBMR, 2008, Vol. 23, pp. 826—836.
Review
For citations:
BELAYa Zh.E., ROZhINSKAYa L.Ya. RATsIONAL'NYY VYBOR FARMAKOTERAPII POSTMENOPAUZAL'NOGO OSTEOPOROZA.EFFEKTIVNOST' I BEZOPASNOST' BONVIVY: OBZOR ZA VOSEM' LET PRIMENENIYa. Osteoporosis and Bone Diseases. 2013;16(2):22-30. (In Russ.)
Views:
6447
Email this article 
